Proactive Investors - Run By Investors For Investors

Moleculin Biotech looks to treat worlds toughest cancers with therapies

Moleculin Biotech (NASDAQ: MBRX) Founder, President and CEO Walter Klemp sat down with Christine Corrado from Proactive Investors New York to talk about their company that is looking for treatments for some of the toughest cancers to fight including Pancreatic.

Klemp telling Proactive,  Moleculin has just raised 15 million dollars which will allow them to continue their trials for the next 18 months/  

View full MBRX profile View Profile

Moleculin Biotech Inc Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use